SCHEMBL6445968

SCHEMBL6445968

COc1ccc(-n2c(-c3ccns3)nc3ccccc32)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 1/20 0.55
ROCK1 Q13464 1/20 0.55
ALDH1A1 P00352 9/20 0.52
MAPT P10636 4/20 0.52
HSD17B10 Q99714 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
CASP1 P29466 1/20 0.52
KDM4E B2RXH2 5/20 0.46
NPSR1 Q6W5P4 3/20 0.46
TSHR P16473 2/20 0.46
LMNA P02545 2/20 0.46
ESR2 Q92731 2/20 0.46
GAA P10253 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.45
POLB P06746 1/20 0.44
RAB9A P51151 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6439149 0.83 ESR2 (0.66) RPS6KB1ROCK1ALDH1A1MAPTHSD17B10
SCHEMBL6440244 0.81 ESR2 (0.70) RPS6KB1ROCK1ALDH1A1MAPTHSD17B10
SCHEMBL6912346 0.80 ALDH1A1 (0.67) RPS6KB1ROCK1ALDH1A1MAPTHSD17B10
SCHEMBL6438264 0.79 RPS6KB1 (0.54) RPS6KB1ROCK1ALDH1A1MAPTHSD17B10
SCHEMBL30746859 0.79 ESR1 (0.67) RPS6KB1ROCK1ALDH1A1MAPTHSD17B10
SCHEMBL6439028 0.79 ESR1 (0.67) RPS6KB1ROCK1ALDH1A1MAPTHSD17B10
SCHEMBL6440228 0.78 RPS6KB1 (0.55) RPS6KB1ROCK1ALDH1A1MAPTHSD17B10
SCHEMBL541002 0.77 HTT (0.70) RPS6KB1ROCK1ALDH1A1MAPTHSD17B10
SCHEMBL6440040 0.77 RPS6KB1 (0.54) RPS6KB1ROCK1ALDH1A1MAPTHSD17B10
SCHEMBL6440213 0.76 ESR1 (0.73) RPS6KB1ROCK1ALDH1A1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1517897-A2 BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS Pfizer Products Inc. (US) 2005-03-30 EP disclosed
US-20040002524-A1 Benzimidazole compounds and their use as estrogen agonists/antagonists CHESWORTH RICHARD (US) 2004-01-01 US disclosed
WO-2004000817-A2 BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS PFIZER PRODUCTS INC. (US) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002524-A1 Benzimidazole compounds and their use as estrogen agonists/antagonists ESR1, GPER1, ESR2 RPS6KB1 3429/4885ROCK1 3937/4885ALDH1A1 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.